Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE study of adjuvant capecitabine chemoradiotherapy after local resection for high-risk T1 lower rectal cancer
jRCT1031180076Suspended
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of capecitabine in rectal cancer and rectal adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 5-year relapse-free survival. Started Feb 2019; status: suspended.
02
Drugs
capecitabine
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on jRCT1031180076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031180076.